ReShape Lifesciences (OTC:RSLS) posted large bottom-line losses in the third quarter, despite a big leap in sales growth. The San Clemente, Calif.–based obesity and metabolic disease treatment developer posted losses of -$28.8 million, or $-106.55 per share, on sales of $3.5 million for the three months ended Sept. 30, for a massive bottom-line slide on […]
Biomet vet Serbousek to succeed Mason as Orthofix CEO | Personnel Moves, August 13, 2019
Orthofix (NSDQ:OFIX) last week named a successor for president & CEO Brad Mason in November, tapping Jon Serbousek as president of its spine business effective August 5. Mason is slated to retire Oct. 31; Serbousek, a 30-year medtech veteran with stints at Biomet, Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) unit DePuy Orthopaedics, is due to […]
Apollo Endosurgery beats on Q2 sales, misses on earnings
Apollo Endosurgery (NSDQ:APEN) reported second-quarter results yesterday that beat analysts’ expectations for sales but missed on earnings. The Austin, Texas-based company reported a net loss of -$8.8 million, or -40¢ per share, on sales of $14.3 million for the three months ended June 30. Analysts on Wall Street were looking for losses per share of […]
Apollo Endosurgery updates labeling on intragastric balloon
Apollo Endosurgery (NSDQ:APEN) said today that the FDA has approved its proposed labeling updates for the Orbera intragastric liquid-filled balloon system, which is used to treat obesity. The goal of the labeling updates is to improve patient safety and they will take effect immediately, according to the Austin, Texas-based company. The Orbera system and Reshape […]
ReShape taps Allergan vet Bandy for CEO | Personnel Moves, April 3 2019
ReShape Lifesciences (NSDQ:RSLS) said last week that it named Allergan (NYSE: AGN) veteran Barton Bandy to replace Dan Gladney in the corner office, effective April 1. Gladney, who announced his retirement in January, is staying on as chairman. Bandy spent a decade at Inamed until its $3.2 billion purchase by Allergan in 2005. “I am […]
ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
Apollo Endosurgery deals Lap-Band to ReShape Lifesciences for up to $17m
Apollo Endosurgery (NSDQ:APEN) said today that it dealt its Lap-Band gastric banding device to ReShape Lifesciences (NSDQ:RSLS) in return for up to $17 million and ReShape’s intra-gastric balloon, which Apollo plans to eventually discontinue. Austin, Texas-based Apollo said the exchange closed yesterday with $10 million in cash and the balloon from ReShape. Further payments of $2 […]
Reshape Lifesciences settles with institutional investors for $700K
Just days after it announced that it had raised $10 million in a registered direct offering, ReShape Lifesciences (NSDQ:RSLS) disclosed in a regulatory filing that it’s paying $350,000 to each of the two institutional investors involved. The U.S. Securities and Exchange Commission filing, dated yesterday, said the money settles a dispute that arose prior to the closing […]
ReShape Lifesciences shares plunge on Q2 release, withdrawn offering
Shares in ReShape Lifesciences (NSDQ:RSLS) have fell 30% today after the weight loss device maker posted second quarter earnings that missed expectations on Wall Street and announced it terminated plans for an upcoming offering. The San Clemente, Calif.-based company posted losses of $35.3 million, or $14.23 per share, on sales of $653,369 for the three months […]
ReShape Lifesciences raises $3m
ReShape Lifesciences (NSDQ:RSLS) said today it inked a private placement deal worth approximately $2.6 million. The San Clemente, Calif.-based company said it plans to float 1.2 million shares of its common stock at $2.05 per share. The offering also includes unregistered warrants to purchase an additional 1.2 million shares at approximately 13¢ per warrant, which the […]
ReShape Lifesciences raises $2m
ReShape Lifesciences (NSDQ:RSLS) said yesterday it inked approximately $1.5 million in offering deals with a number of institutional investors. The San Clemente, Calif.-based company said it will float 374,572 shares of its common stock at a price of $3.92 per share in the registered direct offerings. ReShape Lifesciences will also issue warrants for the purchase of […]
- 1
- 2
- 3
- 4
- Next Page »
